Zoetis has announced the results of a YouGov survey it commissioned to look at pet owner compliance.
The survey, which formed part of the company's 'Respect Antibiotics' campaign, indicates that owners believe they are reasonably compliant. 55% of those surveyed had administered antibiotic tablets to their dog. 88% of those claimed not to have missed a dose, 87% claimed not to have any medication left at the end of the course and 89% administered medication at the same time each day.
Nevertheless, the majority of owners (52%) said they struggled to give their dog a pill and 19% believed they had insufficient information from their vet on the importance of accurate dosing and course completion. 47% said they would prefer to be offered a single treatment given by their vet and most (52%) were prepared to pay a premium for this option.
When it comes to osteoarthritis (OA) medication, the survey found that dog owners are slightly less diligent. Of the 41% surveyed that had given OA/pain medication at some point, 79% claimed not to miss a dose, 62% claimed to finish the course and 87% claimed to administer the medication at the same time each day. Once again, convenience was important, with 48% preferring a monthly treatment, rising to 57% for a long term condition and 52% being prepared to pay a premium for it. Only 17% opted for daily medication.
Andrew Page, product manager for Convenia and Trocoxil said: "We are aware that there may be a disconnect between what pet owners claim to do and what they actually do, especially as nearly half of those surveyed (49%) admitted to forgetting their own daily medication. However, the message that comes out loud and clear is that dog owners would like to be offered medication that can either be given less frequently or administered by their vet, especially as over half of those surveyed had struggled to give antibiotics to their dog and 45% had difficulties giving OA/pain medication."
The BVA has welcomed a Scottish Government consultation on the compulsory microchipping of all dogs in Scotland, launched by Cabinet Secretary Richard Lochhead on 27th December.
Microchipping of all dogs is already a legal requirement in Northern Ireland and will become a requirement in Wales in 2015 and in England in 2016.
BVA President Robin Hargreaves, said: "BVA has long supported the compulsory microchipping of all dogs as a significant welfare measure and so we are delighted that the Scottish Government has launched this consultation.
"Every vet in practice will tell you what a highlight it is to be able to reunite a lost dog and its owner quickly and easily. The more dogs that are microchipped, with correct details on the database, the easier that process becomes meaning fewer dogs sent to kennels and charities."
Ronnie Soutar, President of BVA Scottish Branch, said: "Microchipping is a safe, effective and permanent way to link dogs with their owners and it is an essential part of responsible ownership. It is a small cost in terms of dog ownership with veterinary practices in Scotland offering microchipping at a very reasonable price or at a discount or free as part of a practice promotion. "It is important to remember that microchips are only as useful as the information held on the database and so we must work together with the Scottish Government to ensure that dog owners understand the importance of keeping this information up to date."
The consultation also asks for views on dog licensing and compulsory muzzling of dogs in public areas - measures that BVA has not supported.
Mr Hargreaves said: "We have some serious reservations about the call for all dogs, or dogs of a specific breed, to be muzzled in public areas.
"Under the Animal Health and Welfare (Scotland) Act dogs are afforded the right to exhibit normal behaviour which could be compromised by the requirement to wear a muzzle at all times outside of the home. We hope that respondents to the consultation reject this idea."
The BVA says it will be consulting its members to respond in full to the consultation.
Protexin Veterinary has launched CystoPro, a new product to aid in the management of urinary tract infections in dogs.
According to the company, the key active ingredients in the new product are proanthocyanidins (Type A PACs), derived from cranberries, which work by reducing the ability of E.coli bacteria to infect a dog's urinary tract.
In addition, CystoPro contains the probiotic Enterococcus faecium (NCIMB 10415) E1707 which Protexin says reduces pathogenic bacteria within the gastrointestinal tract thereby lessening the risk of ascending UTIs of faecal origin.
The product also contains Mannan-oligosaccharide (MOS), which Protexin claims binds E.coli and upregulates the innate immune system by attracting phagocytes to opsonise the bacteria.
Lastly CystoPro contains N-acetyl D-glucosamine which is said to reinforce the structure of the Glycosaminoglycan (GAG) layer that lines and protects the bladder urothelium.
CystoPro is available in boxes of 30 and 120 capsules.
The RCVS has extended the deadline for nominations for the RCVS Queen's Medal to 31 January, to allow time for the nominations paperwork to be completed on return from the Christmas and New Year break.
RCVS CEO Nick Stace said: "We received more enquiries about the Queen's Medal over the Christmas period but appreciated that people might welcome a little extra time in the new year to complete and submit their nominations. We're certainly keen to allow anyone who wishes to make a nomination for this very special award the chance to do so."
The Queen's Medal, launched at the House of Lords last November, is a new Honour that will be awarded to a veterinary surgeon for a lifetime of outstanding contributions to the profession and who has dedicated their career to working above and beyond the call of duty in the fields of veterinary medicine or science, or related areas.
It is the most prestigious Honour that the RCVS can bestow, and will be awarded at RCVS Day in London in July.
Full details about the nominations process are available on the RCVS website (www.rcvs.org.uk/Queensmedal). Nominations should be received by the RCVS no later than 5pm on Friday, 31 January 2014.
Fifty young people from low and middle income backgrounds will have the opportunity to learn what it takes to become a vet and prepare to apply to a veterinary school, at a summer school run by the Sutton Trust and the Royal Veterinary College.
The RVC joins nine other UK universities in providing 1900 summer school places this year, helped by a three-year grant of £750,000 to the summer school programme from Barclays.
Each year, around 1,500 applicants apply for 664 places at the seven veterinary schools in the UK.
The 50 successful applicants to the RVC summer school this year will enter a week-long residential course with all expenses covered. The academic programme will focus on Bioveterinary Sciences, Veterinary Medicine and Veterinary Nursing taught by full-time academic staff. It will include practical dissections, clinical skills, farm-based sessions and laboratory periods. The participants will also be given sessions on the application process and interviews.
Sir Peter Lampl, chairman of the Sutton Trust and of the Education Endowment Foundation, said: "I'm delighted that the Royal Veterinary College has joined the Sutton Trust UK summer school programme. Veterinary courses are highly competitive, but it is vital that young people from low and middle income backgrounds have a fair chance to access them.
"Veterinary life is an attractive career choice for many bright young people, not just for the interest and variety of the work but also for the earning opportunities. The 50 students who enrol at the Royal Veterinary College this year will be given the best opportunity to prepare for university courses through our highly successful summer school model." Professor Stuart Reid, Principal at the Royal Veterinary College, said: "For many years the Royal Veterinary College has been focused on widening access to veterinary education to the most able students regardless of their background. The Sutton Trust has a long and successful tradition of supporting under-privileged students into higher education and we are proud to be working with the Trust's summer school programme.
"We hope that the summer school will demonstrate the broad range of exciting opportunities available to students with an interest in veterinary science and encourage more students from non-traditional backgrounds to consider a veterinary career."
Young people interested in applying to Sutton Trust summer schools can find more information at http://www.suttontrust.com/students/uk-summer-schools/
Zoetis has launched Suvaxyn Parvo/E, a combined vaccine which it says provides the earliest protection of gilts against parvovirus and erysipelas.
Parvovirus and erysipelas infections occur primarily in gilts and sows, negatively impacting their reproductive success and the health of their litters - inevitably reducing profitability.
Nigel Lodge, National Veterinary Manager for Zoetis, said: "The combined vaccine will help ensure the health of gilts and sows is not affected by these two infections which are widespread in the pig herd.
"Suvaxyn® Parvo/E gives the earliest protection so that the ability to vaccinate gilts at five months of age will help ensure a good start to their reproductive life. Up to half of all pigs may be carriers of erysipelas and importantly the vaccine has licensed efficacy against both Erysipelothrix serotypes 1 and 2.
"This brings another vaccine to our portfolio, making it one of the largest in the pig sector and confirming the ongoing commitment of Zoetis to the health and welfare of pigs."
Suvaxyn® Parvo/E is an inactivated combination vaccine approved for immunising gilts and sows to prevent reproductive disorders caused by porcine parvovirus and reduce clinical signs caused by Erysipelothrix rhusiopathiae.
Primary vaccination is recommended from five months of age, with two injections given three to four weeks apart, ensuring the second dose occurs at least four weeks before mating. Revaccination should take place three to four weeks before each subsequent mating.
The vaccine comes in 10-dose and 2 X 25-dose packs. For more information, contact your Zoetis Pig Key Account Manager.
Two equine journals have joined forces to create a free online collection of their recent articles on endocrinology to raise awareness of these common disorders and to provide veterinary surgeons with what they say is a definitive source of references all in one place.
The collection of references published by Equine Veterinary Education (EVE) and Equine Veterinary Journal (EVJ) covers a range of topics within the field of endocrinology and includes authoritative review articles on insulin dysregulation2, glucocorticoids and laminitis3 and paraneoplastic syndromes4.
The initiative has been made possible with the support of British Equine Veterinary Association Trust and has been compiled by leading international authorities on equine endocrinology, Professor Philip Johnson, of University of Missouri and Professor Nicholas Frank of Tufts University, Boston and the University of Nottingham.
They say that equine endocrine disorders, such as Pituitary pars intermedia dysfunction (PPID), are becoming more promptly identified and treated, thanks to ongoing research and advances in diagnosis, pharmacokinetics and management protocols.
PPID, or Cushing's, is a progressive neurodegenerative condition that is more easily recognised in its advanced form in older horses. Surveys show a PPID prevalence rate of up to 22% in horses over the age of 155, with the odds of developing clinical signs associated with PPID increasing by approximately 20% per year after this age.
Insulin dysregulation (ID), characterised by increased insulin response to oral sugars, hyperinsulinaemia and insulin resistance, is identified in both PPID and equine metabolic syndrome (EMS)2. Both PPID and EMS have been linked to the development of recurrent laminitis with subsequent high risk of mortality6. The exact mechanisms which link insulin to laminitis remain to be clarified1 but this online collection highlights several studies, which partially address this important jigsaw7-12.
Best practice for the management of EMS is outlined by Professors Nick Frank and Ray Geor in the December issue of EVE13. The first goal is to induce weight loss, and guidelines for designing diets for obese equids are provided. Exercise and dietary management14 have been shown to reduce the clinical signs and indices of inflammation in equine metabolic syndrome13 - 15, however, further studies are needed to quantify the efficacy of these management changes on long-term outcomes.
The online collection also includes several studies addressing the diagnosis of PPID. The value of plasma adrenocorticotropin hormone (ACTH), when interpreted with seasonally adjusted reference ranges, is discussed by several authors18-20. Professors Frank and Geor advocate it as the most readily accessible test for monitoring PPID cases in a field setting, although they maintain that the thyrotropin- releasing hormone (TRH) stimulation test is more sensitive and therefore has advantages when diagnosing PPID in its early stages13.
Pergolide has emerged as the drug of first choice for treatment of PPID13. While many vets recommend the early introduction of medication in the hope that it may avert the specter of laminitis, at present, there are no trials comparing pergolide with alternatives. Furthermore, there have been no long-term studies to show that horses treated with pergolide before the onset of clinical signs of PPID have better outcomes, including a reduced incidence of developing laminitis, than horses in which treatment is delayed until clinical signs become apparent.
Professor Celia Marr, Editor of Equine Veterinary Journal said: "Better control of PPID and insulin dysregulation should lower the risk of laminitis to help improve the health and longevity of many predisposed horses and ponies.
"Raising awareness of the benefits of early diagnosis and sharing the latest research on these and other associated conditions are imperative to provide horse owners with the best diagnostic and treatment programmes for their horses. However, it is easy to under-estimate obesity: horse owners need to think about improving management of their horses' feeding and exercise in order to avert problems before they become a veterinary issue."
References
Animalcare has announced the launch of Thiafeline (Thiamazole 2.5mg and 5mg) for the management of hyperthyroidism in cats.
An estimated 12% of UK cats over the age of nine suffer from hyperthyroidism², which could equate to almost 350,000 cats³. In one study, 92% of cats diagnosed with hyperthyroidism were stable after four weeks treatment (on the twice daily 2.5mg dosing) with thiamazole¹
Thiafeline is presented as a blister pack, which Animalcare says offers the benefits of easy dispensing, improved stock control and no nurse exposure during dispensing for increased safety in practice. This format also allows pet owners to monitor the dosage and quantities easily, for an uninterrupted course of medication.
Animalcare says that whilst many of the clinical signs for hyperthyroidism are easily recognised, it understands that diagnosis is not always straightforward. For this reason, the company has produced support materials for Thiafeline users including diagnosis best practice charts for use within practice and a pet owner awareness package for use in waiting rooms.
Beverley Hammond, Product Manager for Thiafeline said: "While initial signs associated with hyerperthyroidism can appear quite mild it is important for pet owners to understand that if left untreated the condition can lead to serious secondary complications. It's easy for owners to assume that the signs they are seeing are simply related to old age so our campaign will aim to increase the amount of owners bringing their cats for senior pet checks and also ensure that vets are following the best practice procedures to reach a definitive diagnosis."
The National Office of Animal Health (NOAH) has announced the results of a survey of 2000 pet owners which found that 77% believe their pet's health is as or more important than their own, with 16% even claiming to visit the vet more often than their doctor.
The survey marks the launch of NOAH's newly revamped website: www.pethealthinfo.org.uk and the second year of its 'I Heart My Pet' campaign. The campaign is designed to encourage owners to seek expert preventative healthcare advice for their animals and was created in response to NOAH figures which show that despite our love for our pets, many owners neglect to take preventative healthcare measures such as vaccination and worming.
The survey also showed that vets remain the most trusted source of advice about pet healthcare (86%), despite the rise of the Internet. Other pet and animal experts came second at 53%, followed by independent pet healthcare websites in third (47%).
The survey usefully identified the three priorities pet owners have when choosing a veterinary practice:
NOAH Chief Executive, Philip Sketchley said: "Once again we're encouraged by how seriously British pet owners take the healthcare needs of their animals and the love they clearly have for their pets. As we move into the second year of our 'I Heart My Pet' campaign, we're calling on all pet owners in the UK to share this love by getting involved with the campaign and visiting our revamped www.pethealthinfo.org.uk site for independent, expert advice to keep their pets happy and healthy all year round. We're encouraging veterinary and pet professionals to get involved and join the conversation on the site as well as through our social media communities on Twitter (@IHeartMyPet) and Facebook (IHeartMyPetUK).
"The website continues to include a wealth of completely unbranded information on animal healthcare as well as exciting resources for owners, but is now in a fresh new format - much more interactive and designed for use with mobile devices. We still encourage vet practices and pet businesses to link to the site, and to recommend it to support their own advice and information", he added. "In addition, we can offer veterinary and pet professionals materials such as campaign window stickers to help engage their audiences."
The BVA has called on the Government to introduce a ban on the keeping of primates as private pets.
Veterinary surgeons at the BVA have been considering the potential welfare concerns of such animals in response to an Efra select committee inquiry on the issue. They have concluded that it is almost impossible for private owners to provide primates with appropriate care as defined by the Animal Welfare Act 2006.
BVA President Robin Hargreaves said: "We appreciate that many people who keep primates privately care deeply for their pets and do their utmost to provide for them appropriately. However, primates are long-lived, intelligent, socially-complex animals and we can think of no circumstances where they would benefit from being kept as a pet.
"Primates cannot be kept on their own. They need at least one companion in order to express natural behaviour. They require both an indoor and outdoor enclosure to ensure adequate exercise and exposure to UV light, and each species has specific dietary requirements.
"These animals are not domesticated companions like dogs and cats, or even livestock, and are extraordinarily difficult to care for properly. Very few people can provide the necessary resources to meet their welfare needs. We therefore favour a ban on the keeping of primates as private pets."
The Association says that as part of the consultation, it considered the possibility that primate welfare could be improved through better regulation or licensing but members did not feel these options went far enough given the difficulties involved in meeting primates' basic welfare needs.
The only exception to the ban recommended by the BVA would be to allow individuals who are working in partnership with accredited zoos to breed primates for conservation purposes.
BVA also recognises that a ban could not be enforced immediately and effective plans, including an appropriate transition period, would be needed to secure suitable accommodation for existing pet primates.
As the House of Lords begins its debate on the religious slaughter of farm animals, the RSPCA is calling for all to be pre-stunned.
More than 900 million farm animals are slaughtered for meat in the UK every year. The vast majority are stunned pre-slaughter. However, the law permits the Jewish and Muslim communities to kill animals by religious methods without any form of pre-stunning.
The RSPCA says that while it recognises that religious beliefs and practices should be respected, it also believes that animals should only be slaughtered under the most humane conditions.
RSPCA Dr Julia Wrathall, head of the RSPCA's farm animal science department said: "Farm animals deserve to be treated with care and respect throughout their lives, from the time they are born right up to their final moments in the abattoir.
"We want to see all animals rendered unconscious before slaughter. Until that time we are calling for clear labelling so shoppers are armed with information that can enable them to make an informed choice about whether they buy meat from animals which have not been stunned before slaughter.
"Until there is better, universal labelling, shoppers should look for the blue and white Freedom Food label. Meat produced under this RSPCA assurance scheme comes from animals inspected to the RSPCA's farm animal welfare standards which do not permit slaughter without pre-stunning."
According to the charity, scientific research shows that slaughtering animals without pre-stunning (to render them insensible to pain and distress) can cause unnecessary suffering.
David Bowles, head of public affairs for the RSPCA, who has written a report for the House of Lords debate, added: "We know this is a subject that our supporters feel passionately about. We share their welfare concerns and that is why we have continued to campaign for religious slaughter to be discussed at the highest possible levels."
The RSPCA works with the Food Standards Agency (FSA) to publish the results of the FSA's Animal Welfare Survey undertaken in abattoirs across Great Britain.
The latest survey* results shows:
The RSPCA believes mandatory labelling should be introduced so that all meat that has not been stunned is labelled and says it will press for European rules on this in 2014.
Ceva Animal Health has announced that it has made its cardiology webinar series, first broadcast in November and December 2013, available to view on demand at: www.cardaliscpd.co.uk.
Featuring some of the UK's leading veterinary cardiology specialists, the webinars that can be watched on demand include:
Each webinar lasts for around 1.5 hours. CPD certificates are then available after answering questions relating to each webinar.
Senior product manager Fraser Broadfoot MRCVS said: "We have been overwhelmed by the response to this webinar series, which shows how strong the demand is for high quality cardiology CPD. Ceva remains committed to continue supporting veterinary professionals by carrying out ongoing cardiology seminars, webinars and online CPD programmes."
For further information, please email Ceva Animal Health on customerservicesuk@ceva.com.
The RCVS has launched a survey asking recent graduates from UK veterinary schools to share their experiences of the role played by extra-mural studies (EMS) while studying for their degree.
The aim of the online survey, which has been emailed to all of the 2012 and 2013 UK veterinary graduates for whom the College holds email addresses, is to take a snapshot of how EMS placements - whether pre-clinical or clinical - are working in practice and their value in educational terms.
Christine Warman, RCVS Head of Education, said: "In 2009 we carried out a review into EMS arrangements and, in light of this, we want to gather evidence on current practice in order to build up a picture of how EMS is now working and the role that it plays in the learning process for veterinary students. This evidence will inform any future discussions about EMS.
"So, for example, we would like to find out what students gained from EMS that they could not have learnt from their core studies alone and gather further information on the process of identifying and arranging EMS placements."
Recent graduates taking part in the survey, which takes around 10 to 15 minutes to complete, can supply their name and email address or, alternatively, there is the option of responding anonymously. The survey should be completed by Friday 14 February. Those 2012 and 2013 graduates who have not received an email with the link to the survey, and who wish to take part, should email: education@rcvs.org.uk
For more information on EMS, or the survey, contact the RCVS Education Department on 020 7202 0791 or education@rcvs.org.uk. Further guidance about EMS for both students and placement providers can be found at www.rcvs.org.uk/ems which includes a link to the RCVS Find a Vet service where students can search for practices providing EMS.
Veterinary Practices are being urged to come forward and enter their PR campaigns for this year's Veterinary Marketing Association (VMA) PR Award for 2013.
The aim of the PR Award is to recognise the value that media and public relations can add to the marketing mix, says award sponsor, Jane Manning of Splash Communications.
Jane said: "PR comes in many forms, including social media, but you don't always need big budgets to deliver the most effective campaigns. Regional press, newsletters and radio or local TV broadcasts are all ways that vets can promote their business or specific initiatives. We know that many practices are highly active across many of these mediums, helping to promote the practice or specific initiatives to a local audience."
She added: "The award is given to the company, organisation or veterinary practice that has delivered the most innovative and effective PR campaign during the previous year, as judged by a panel of industry professionals. This can be a single 'one-off' event or article, or a sustained campaign over a given period".
The winner and two highly commended entries will be announced at the VMA Awards on Friday 14th March 2014, at The London Lancaster Hotel.
Deadline for entries is Friday 31st January 2014. Further information on the awards and ticket application forms are available at the VMA's website: www.vma.org.uk or by calling 0844 561 6157.
The Animal Health Trust is calling for all small animal practitioners to help with a prospective survey study on breed differences in clinical features in canine hyperadrenocorticism.
The Trust is asking vets that diagnose a case of spontaneous hyperadrenocorticism to complete an online questionnaire at bit.ly/aht-cushing.
The questionnaire should take 10 minutes to complete and all the information will be processed anonymously. Each questionnaire submitted has a chance to win a £100 Amazon voucher. On completing the survey, participants can ask to be notified of the results of this study when available.
Researchers say they hope this data will help veterinary surgeons in the diagnosis of canine hyperadrenocorticism, and ask that everyone helps spread the word about the study.
If you have any queries about this study, please contact michael.bennaim@aht.org.uk
Petplan has been voted Best Insurance Provider in the seventh annual Your Cat and Your Dog Product Awards.
This is the sixth consecutive year Your Cat and Your Dog readers have voted Petplan number one, in response to a survey completed by thousands of pet owners.
Isabella von Mesterhazy, Head of Marketing at Petplan said: "To be independently voted number one provider by pet owners means so much, particularly as this is the sixth time we have been awarded this honour.
"Petplan's Covered for Life policy is the original lifetime policy - we were the first insurer to offer this type of policy and cover. This, combined with over 36 years' experience in the pet insurance marketplace means Petplan truly understands what pet owners need and want from their pet insurance. We settle 97% of claims successfully and 90% of customers renew each year. Moreover, we paid out over £180 million in claims in 2013, the majority directly with the vet, which leaves owners able to concentrate on supporting their pet back to full health rather than worrying about vet bills."
Elanco has announced the results of a survey it conducted amongst European dermatology diplomates which found that nearly 90% of them consider Comfortis (spinosad) is the first choice of flea control for cats and dogs.
The research was conducted at the European Society of Veterinary Dermatology (ESVD) and European College of Veterinary Dermatology (ECVD) Congress 2013. 49 Dip ESVD holders from around Europe were asked:
Research has shown that dermatological cases account for approximately 20% of small animal consultations conducted by general practitioners1. According to Elanco, further industry investigations have found that skin diseases are two to three times more common than the next disease category, and dermatological problems are a common secondary reason for an examination.
Anna Jackson, national veterinary manager at Elanco Companion Animal Health, said: “Skin diseases are a huge part of a practicing vet’s workload and one which can prove challenging to effectively address. By creating a fast acting oral flea control product that can work alongside other topical dermatological treatments, we’re helping to alleviate the discomfort and consequences of flea allergy dermatitis, which is one of the most common causes of skin disease. It’s fantastic to receive such strong endorsements from some of the leading dermatologists in Europe and this underlines the benefits of using Comfortis for flea control.”
Reference
Boehringer Ingelheim Vetmedica has launched trial size Seraquin dispensing strips so clients can try a week's supply of the veterinary joint support supplement for cats and dogs.
Rob Lucy, brand manager for Seraquin, said: "With 9 out of 10 dogs and cats eating Seraquin as a treat, the new dispensing strips are a great way to enable pet owners to experience just how palatable it is."
Each pack of Seraquin dog dispensing strips contains 40 strips of 10 chewable tablets. Each pack of Seraquin cat and small dog dispensing strips contains 10 strips of 20 chewable tablets.
Boehringer says that for each pack of Seraquin dog dispensing strips purchased, veterinary practices will get one pack of Seraquin cat and small dog dispensing strips free. In addition, the company will make a £20 donation to Hounds for Heroes on behalf of each practice that orders Seraquin Dispensing Boxes. The donations will help to buy, train and support an assistance dog for an injured or disabled man or woman from the UK armed forces or civilian emergency services.
For further information, contact your Boehringer territory manager.
Zoetis has announced the launch of Apoquel (oclacitinib maleate), a new treatment for pruritus associated with canine allergic dermatitis and the clinical manifestations of atopic dermatitis.
Uniquely, the new treatment inhibits the JAK enzyme, a protein that is integral to the signalling pathway of cytokines that are pro-inflammatory or have a role in allergic and itch response.
According to the company, pruritus affects about one in six dogs whose owners seek veterinary help, and about half of all itchy dogs will have an underlying allergic skin condition for which the new product would be indicated.
Zoetis says that because Apoquel targets the specific pathways of pruritus (itch) and inflammation, it is less likely to cause unwanted side effects than glucocorticoids and demonstrates anti-pruritic efficacy within four hours.
Pascal Prélaud, a dermatology specialist from Paris, who took part in the clinical development programme of Apoquel, said: "When a dog develops an itch related to an allergy, it can be life-disrupting for the dog and the entire family. I've learned firsthand the fundamental difference this treatment can make to a dog and its owners in stopping the itch, but without many of the side-effects that are common with steroids.
Zoetis reports that in clinical trials, Apoquel demonstrated a good safety profile and efficacy for the treatment of pruritus and resulted in improved skin lesions in dogs diagnosed with a number of allergic skin diseases as well as atopic dermatitis and treated either short or long term. The decrease in itch scores was observed by pet owners within 24 hours of administration, and pruritus continued to decrease compared to baseline until the end of the study. Skin lesions scores assessed by veterinarians were significantly improved after one week and continued to improve long term during the studies (four months).
Apoquel is a POM. Apoquel tablets, dosed at 0.4 to 0.6 mg/kg, are administered orally, twice daily for up to 14 days, and then administered once daily for maintenance therapy if medium- to long-term treatment is required, such as in dogs with seasonal skin allergy and atopic dermatitis.
Ceva Animal Health has launched Vectra 3D, a broad spectrum topical ectoparasiticide for dogs which is effective against fleas, ticks and flies.
Vectra 3D contains a formulation of a brand new active called dinotefuran, pyriproxyfen and permethrin.
According to the company, Vectra 3D provides a rapid flea kill within two hours for dogs on current treatment and complete protection against the major vectors: fleas, ticks, sand flies, mosquitoes and stable flies1. Additionally, because dinotefuran kills on contact, it is claimed to reduce the incidence of flea feeding1.
Vectra 3D is applied in a line from the base of the tail to the neck using a patented applicator with an elongated tip, designed to make it easy to apply the product through the hair directly onto the skin. The applicator is also designed to provide accurate dosing without making any mess, as nothing comes out until the tube is squeezed.
Ceva highlights that the number of people travelling with their pets has increased by 61% since 20122, and that Vectra 3D is the only topical ectoparasiticide that offers repellent action against sand flies for one month, together with protection against mosquitoes and stable flies.
Julia Wood, product manager at Ceva Animal Health said: "Vectra 3D is an innovative formulation which uses a unique, easy-to-administer applicator to provide complete protection against fleas, ticks and flies. And with spring nearly upon us, it's time to start talking to clients about flea treatments, such as Vectra 3D."
To support the launch of Vectra 3D, Ceva is hosting a series of CPD meetings at venues across the UK. Accounting for two hours CPD, the afternoon meetings will cover vector-borne diseases, the importance of ticks in the UK and product information on Vectra 3D. They will be presented by Ian Wright BVMS BSc MSc MRCVS and Richard Wall BSc MBA PhD FRES and take place at:
For further information, contact your Ceva Animal Health territory manager or email Ceva Animal Health on customerservicesuk@ceva.com.
Bayer Animal Health has announced the results of a survey1 which shows that despite 80% of dog owners being aware of lungworm (Angiostrongylus vasorum), 85% of dogs remain unprotected against the parasite.
The survey, which was carried out amongst 1,000 dog owners, also found that more than 5% had encountered lungworm in their own dogs. However, only 15% of owners treat their pet against parasites on a monthly basis, with the remainder admitting to missed routine lungworm worming treatments or not treating at all.
Bayer highlights evidence from the Royal Veterinary College2, which confirms the lungworm parasite has spread across the UK from its traditional habitat in the south of England and Wales, and is now widespread in Central England, also reaching northern regions and Scotland, with one in five vet practices nationwide reporting at least one case of the parasite. In another survey of 150 veterinary practices across the UK a total of 952 suspected cases were reported (157 laboratory confirmed), with 81 deaths thought to have been caused by the parasite3.
To encourage more pet owners to take action, Bayer will launch a consumer campaign called 'Act on Lungworm' in March. The campaign will include the world's first 24-hour radio station for dogs and their owners, 'Hound Waves', broadcasting live from Crufts on Friday 7th March. The event will also see the launch of a new television and advertising campaign from Bayer.
For veterinary professionals, the campaign launch will also include online videos detailing the 'ACT on Lungworm' veterinary support and showing the new television advertisement exclusively to vets before the national launch.
Caroline Braidwood, Group Product Manager at Bayer Animal Health said: "After launching the 2013 lungworm awareness campaign and providing owners with a social media platform, we quickly began to recognise the enthusiasm that exists to encourage action.
"We received feedback from owners who had tragically lost their pets to lungworm, and whilst we were pleased that we were helping to raise awareness, we became conscious that we needed to do more to prevent dogs from dying unnecessarily. Our 2014 campaign focus has come as a direct result of talking to these owners and providing individuals like Sandra Stevens with a platform to discuss their experiences in the hope that more owners will take action before it is too late."
'ACT on Lungworm' is part of Bayer Animal Health's wider 'It's a Jungle Out There' parasite protection initiative. Further information is available at www.facebook.com/jungleforpets
Novartis Animal Health has announced the launch of a campaign to improve awareness of and improve education about atopic dermatitis (AD), to coincide with the 10th anniversary of Atopica.
As part of the campaign, the company is inviting veterinary surgeons to take part in an online survey for the chance to win an iPad mini: www.surveymonkey.com/s/atopica
In addition, Novartis says it will be offering all sorts of new educational materials for both vets and owners, including research into current trends and attitudes towards AD, insights from experts in the field, and case studies.
Ricardo Garvao, Category Manager for Atopica said: "This year marks an important milestone for the Atopica brand that wouldn't have been possible without the backing of so many vets. Continued investment by Novartis Animal Health into research and education seems a fitting way to extend thanks for this support and so forms one of the key elements of the 'Decade of Comfort' campaign. I am constantly amazed at just how dedicated and hard-working vets are and am immensely proud that Novartis Animal Health shares their goal to help pets remain happy and healthy."
Vetsonic has taken over the marketing of Cavalesse, the oral nutritional supplement for horses that are prone to skin allergies, such as sweet itch.
Cavalesse contains a formulation of water-soluble vitamins and minerals, administered daily via a special pipette, either by sprinkling over a small handful of feed or adding to a treat. Vetsonic claims the supplement helps horses maintain a healthy skin and promotes normal immune function.
Ray Rochester, Managing Director of Vetsonic said: "It's an exciting phase in the development of Vetsonic which will see us rapidly expanding in the increasingly competitive small animal and equine market. Cavalesse is a welcome addition to our portfolio."
For further information, contact Vetsonic customer services on 01653 695333.
The Animal Welfare Foundation (AWF) has produced a leaflet which guides pet owners through the euthanasia decision making process.
The leaflet 'Saying goodbye - the ultimate kindness' explains why euthanasia may be the most caring option, the choices owners have, the different ways euthanasia may be performed and what happens next. It also addresses the emotions owners may go through when deciding to put their pet down.
AWF Chairman Tiffany Hemming said: "As vets we often see pet owners struggle with letting their pet go. Guilt may be the strongest emotion owners feel when deciding to put their pet down. We wanted to guide owners through this difficult time in a sensitive way and encourage them to ask questions and work with the vet to help them come to terms with the end of their pet's life.
"While the leaflet is aimed at pet owners we hope vets find it a useful communication tool during this distressing time for their clients."
To see all AWF leaflets including 'Pre- and post-operative care', 'Pet travel', 'Pets and poisons', and 'What makes my pet happy' visit http://www.bva-awf.org.uk/pet-care-advice.
Practices can order batches of the leaflets for clients in return for a donation to AWF by contacting bva-awf@bva.co.uk.
A new study from the University of Surrey, published today in the journal PLOS One, has identified the specific effects of a malformation which affects affects toy breeds.
According to researchers, Chiari malformation has become prevalent as a result of selective breeding and affects many toy dog breeds which have been bred to look more doll-like, including Griffon Bruxellois, Cavalier King Charles Spaniels, Chihuahuas and their crosses.
Researchers took brain, skull and vertebrae measurements of 155 Griffon Bruxellois and compared dogs affected by the condition with normal Griffons. They discovered that Griffons with the disease had taller foreheads and that it had also caused the shape of the brain to change, with severely affected animals having their cerebellum pushed underneath the main part of the brain.
The researchers say that although it can be asymptomatic, in many dogs Chiari malformation can cause headaches, problems with walking or even paralysis.
The condition can also affect humans and the University is working with human geneticists at the University of Montreal, in the hope that better understanding of the condition will lead to improved treatment for both dogs and humans.
Lead author, Dr Clare Rusbridge from the new School of Veterinary Medicine at the University of Surrey, said: "Chiari malformation can be described as trying to fit a big foot into a small shoe. It can be very painful, causing headaches and pressure on the brain and can result in fluid filled cavities in the spinal cord. Our latest discoveries will be significant in driving this research forward and hopefully allow us to identify which genes may be associated with the condition.
"Our next steps will be to apply our technique to other breeds with Chiari malformation and investigate more sophisticated ways of screening, so that risk of disease can be detected more easily, at an earlier age and with a single MRI scan.
"We want to engage breeders and give them practical advice about the condition, but it is also important that the public recognises that breeding dogs in a certain way to influence how they look might not be in the animal's best interest. There are responsible breeders out there, who have invested in screening and who are breeding for health as well as producing attractive puppies, and it is vital that people only look to buy from them."